A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome

被引：0
|
作者：
Komrokji, Rami S. [1 ]
Carraway, Hetty E. [2 ]
Germing, Ulrich [3 ]
Wermke, Martin [4 ]
Zeidan, Amer M. [5 ]
Fu, Eric [6 ]
Rueter, Bjoern [7 ]
Burkard, Ute [7 ]
Osswald, Annika [7 ]
Foran, James M. [8 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL 33612 USA
[2] Cleveland Clin, Taussig Canc Inst, Leukemia Program, Cleveland, OH USA
[3] Heinrich Heine Univ Dusseldorf, Univ Klinikum Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[4] Tech Univ, Med Fac Carl Gustav Carus, NCT UCC ECTU, Dresden, Germany
[5] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT USA
[6] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[7] Boehringer Ingelheim Pharm GmbH & Co KG, Biberach, Germany
[8] Mayo Clin, Dept Hematol & Med Oncol, Jacksonville, FL USA
来源：
HAEMATOLOGICA | 2022年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2742 / 2747
页数：6
相关论文
共 50 条
  • [31] TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumours: Dose escalation part of a multicenter open-label phase I trial (SAKK 65/16)
    Hess, D.
    Colombo, I.
    Haefliger, S.
    Bastian, S.
    Rabaglio, M.
    Metaxas, Y.
    Eckhardt, K.
    Kopp, C.
    Hayoz, S.
    Mueller-Schoell, A.
    Kloft, C.
    Sessa, C.
    Stathis, A.
    Joerger, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S490 - S490
  • [32] A Randomized Study to Determine the Optimal Dose of Darbepoetin Alfa in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
    Harada, Hironori
    Shibayama, Hirohiko
    Jang, Jun Ho
    Shimazaki, Ryutaro
    Mitani, Kinuko
    Sawada, Kenichi
    Kim, Hyeoung-Joon
    BLOOD, 2014, 124 (21)
  • [33] Phase 1b/2, open-label, multicenter, dose escalation and expansion trial of intratumoral SD 101 in combination with pembrolizumab in patients with metastatic melanoma
    Ribas, A.
    Gonzalez, R.
    Drabick, J.
    Kummar, S.
    Agarwala, S.
    Nemunaitis, J.
    Coffman, R.
    Berman, C. J.
    Schmidt, E.
    Chartash, E.
    Guiducci, C.
    Candia, A.
    Janssen, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.
    Gort, Eelke
    Johnson, Melissa Lynne
    Hwang, Jimmy J.
    Pant, Shubham
    Dunzinger, Ulrich
    Riemann, Kathrin
    Kitzing, Thomas
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations
    Heymach, John
    Opdam, Frans
    Barve, Minal
    Gibson, Neil
    Sadrolhefazi, Behbood
    Serra, Josep
    Yamamoto, Noboru
    CLINICAL LUNG CANCER, 2023, 24 (02) : e65 - e68
  • [36] A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S69 - S70
  • [37] A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Beyne-Rauzy, Odile
    Mufti, Ghulam
    Mittelman, Moshe
    Muus, Petra
    Boekhorst, Peter Te
    Sanz, Guillermo
    del Canizo, Consuelo
    Guerci-Bresler, Agnes
    Nilsson, Lars
    Platzbecker, Uwe
    Luebbert, Michael
    Quesnel, Bruno
    Cazzola, Mario
    Ganser, Arnold
    Bowen, David
    Schlegelberger, Brigitte
    Aul, Carlo
    Knight, Robert
    Francis, John
    Fu, Tommy
    Hellstrom-Lindberg, Eva
    BLOOD, 2011, 118 (14) : 3765 - 3776
  • [38] A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
    Verstovsek, S.
    Talpaz, M.
    Ritchie, E.
    Wadleigh, M.
    Odenike, O.
    Jamieson, C.
    Stein, B.
    Uno, T.
    Mesa, R. A.
    LEUKEMIA, 2017, 31 (02) : 393 - 402
  • [39] A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
    S Verstovsek
    M Talpaz
    E Ritchie
    M Wadleigh
    O Odenike
    C Jamieson
    B Stein
    T Uno
    R A Mesa
    Leukemia, 2017, 31 : 393 - 402
  • [40] Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study
    Kudo, Toshihiro
    Murai, Yoshiyuki
    Kojima, Yoshitsugu
    Uehara, Kenji
    Satoh, Taroh
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 354 - 362
12345